In solid tumors, the most commonly targeted tumor-associated antigens (TAAs) include CEA, HER2, GPC3, and EpCAM, whereas tumor-specific antigens (TSAs) are relatively rare, which significantly limits the application of CAR-T cell therapy in solid tumors. The gene discussed is ERBB2; the disease is neoplasm.